Document is current
Any future updates will be listed below
-
Authors
Moser, Sarah C. https://orcid.org/0000-0002-1678-4079
Khalizieva, Anna
Roehsner, Josef
Pottendorfer, Elisabeth
Kaptein, Milo L. https://orcid.org/0009-0009-5863-9169
Ricci, Giulia
Bhardwaj, Vivek
Bleijerveld, Onno B. https://orcid.org/0000-0002-9395-2347
Hoekman, Liesbeth https://orcid.org/0000-0002-3552-6390
van der Heijden, Ingrid https://orcid.org/0000-0003-2849-8253
di Sanzo, Simone
Fish, Alexander
Chikunova, Aleksandra https://orcid.org/0000-0002-2818-0539
Haarhuis, Judith H. I.
Oldenkamp, Roel
Robbez-Masson, Luisa
Sprengers, Justin
Vis, Daniel J.
Wessels, Lodewyk F. A. https://orcid.org/0000-0002-1656-6995
van de Ven, Marieke https://orcid.org/0000-0001-6779-9353
Pettitt, Stephen J.
Tutt, Andrew N. J. https://orcid.org/0000-0001-8715-2901
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Rowland, Benjamin D. https://orcid.org/0000-0002-0694-8463
Völker-Albert, Moritz
Mattiroli, Francesca https://orcid.org/0000-0002-1574-7217
Brummelkamp, Thijn R. https://orcid.org/0000-0002-3066-7071
Mazouzi, Abdelghani https://orcid.org/0000-0003-0298-6304
Jonkers, Jos https://orcid.org/0000-0002-9264-9792
- License Information
-
More Information
Article History
Received: 2 April 2024
Accepted: 15 July 2025
First Online: 13 August 2025
Competing interests
: M.V.-A. is a shareholder of MoleQlar Analytics. T.R.B. is a co-founder and shareholder of Scenic Biotech B.V. J.J. has received research funding from Artios Pharma. C.J.L. receives and/or has received research funding from AstraZeneca, Merck KGaA, Artios, Neophore and FoRx; received consultancy, SAB membership or honoraria payments from FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, GlaxoSmithKline, Dawn Bioventures, Blacksmith Medicines, ForEx and Ariceum; and has stock in Tango, Ovibio, Hysplex, Tesselate and Ariceum. A.N.J.T. is or has been a consultant for AstraZeneca, Merck KGaA, Artios, Pfizer, Vertex, Gilead and MD Anderson Cancer Centre; and has received grant and/or research support from AstraZeneca, Myriad and Merck KgaA. C.J.L. and A.N.J.T. are named inventors on patents describing the use of DNA repair inhibitors and stand to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme and also report benefits from this scheme associated with patents for PARP inhibitors paid to the research accounts for C.J.L. and A.N.J.T. at the Institute of Cancer Research. All other authors declare no competing interests.
